Reflecting on our leadership in blood cancer: a Q&A with Winselow Tucker

September 13, 2021

In what ways has Bristol Myers Squibb helped move the needle towards improved patient care for those living with blood cancer?

Every day we leverage the latest science and technology to develop therapies that push beyond what is currently available to patients living with rare blood cancers and disorders.

Through our strong heritage and robust portfolio of treatment options in multiple myeloma, we have shaped the treatment paradigm as demonstrated through our long experience with IMiD® agents and subsequent research into new CELMoD® agents. We are also working hard to address the burden of relapses for multiple myeloma and lymphoma patients by exploring alternate pathways including CAR T cell therapy that may contribute to patients living longer.

There has been tremendous progress in leukemia in which our multiple therapies for acute (fast-growing) myeloid leukemia have helped to broaden the treatment landscape including targeted therapies directed against mutations. We have also established our therapeutic leadership across the myeloid space, with new treatment options for both myelodysplastic syndromes (MDS) and myelofibrosis (MF) – diseases that previously had been without innovation for more than a decade.

We understand that with each advancement comes a new opportunity to potentially help patients achieve complete remission, decrease the likelihood of relapse and extend overall survival. Through our broad clinical development program and diverse portfolio, we are evaluating a range of potential new therapies and combinations for blood cancers that remain hard-to-treat, in an effort to leave no patient behind.

Winselow Tucker, Senior Vice President and General Manager, U.S. Hematology, Bristol Myers Squibb

Winselow Tucker, Senior Vice President and General Manager, U.S. Hematology, Bristol Myers Squibb

What hematologic needs is Bristol Myers Squibb actively working to address?

In addition to harnessing the power of science to address some of the most complex diseases of our time, we aspire to be the most inclusive, patient-centered biopharmaceutical company. As such, we are committed to delivering transformative medicines that also improve the health outcomes of medically underserved and diverse patient populations. This commitment involves transforming our business and the inclusive collaboration of our workforce, partners and communities to drive innovation with a health equity lens and mindset.

Through our diversity, equity and inclusion commitments, we are focusing on clinical trial diversity that will lead to better science and patient outcomes, workforce representation, health equity, supplier diversity and a robust employee giving program.

What achievements do you treasure the most through your work with Bristol Myers Squibb?

I am most proud of the relationships we have forged through meaningful partnerships with advocacy groups and other industry leaders that aim to improve the patient experience and outcomes. We’ve combined forces to educate and reach more audiences across the globe, with the goal of improving access to care for those who need it.

Some of the ways we do this are happening right now. Bristol Myers Squibb participates in The Leukemia & Lymphoma Society (LLS) event Light The Night®, an annual event where blood cancer survivors and supporters join to walk and raise funds for research, advocacy and patient services. I previously served as the company's Corporate Walk Chair, which was such an honor. During the walks, participants carry colored lanterns that represent their personal ties to blood cancer and the organization’s goal of “bringing light to the darkness of cancer.” Last year, the Bristol Myers Squibb team raised nearly $860,000 for the blood cancer community, even as the walks were converted to virtual events for the safety of participants.

We also recognize Blood Cancer Awareness Month each September by bringing attention to people living with blood cancers and their loves ones who are also impacted through education and creating visibility around these rare diseases.

We believe it’s not simply about giving patients more life but offering the possibility of a better life, which we aim to achieve through these partnerships that amplify our efforts in this community.